Dipesh Uprety MD FACP· @DipeshUpretyMD · X·· 14 小时前评分70
正文 · 原文
DeLLphi-305 @NEJM #ESMO26
➡️Pts with ES-SCLC without progression after initial chemo-IO randomized to tarlatamab–durvalumab with durvalumab as 1L maintenance therapy
➡️ Md OS 21.1 mo (tarla arm) vs 12.7 months
➡️Md PFS 7.4 mo (tarla arm) vs 1.9 mo
Practice changing and now a new standard of care
#LCSM @OncoAlert
https://www.nejm.org/doi/full/10.1056/NEJMoa2609482?query=featured_home
39 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Dipesh Uprety MD FACP · x.com